Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 30 patients with chronic diabetic or traumatic peripheral neuropathic pain
- Dose used in the study
- Ultramicronised PEA (PEA-um), 1200 mg per day by mouth, added to existing stable therapies
- Duration
- 40 days
- What was measured
- Visual Analogue Scale (VAS) pain score, Neuropathic Pain Symptom Inventory (NPSI) score, and EQ-5D quality-of-life score, at baseline, 10 days and 40 days
What the authors reported
VAS pain score fell from 8.20 to 6.40 within 10 days (P<0.002) and to 5.80 by 40 days (P<0.001). NPSI score improved from 5.2 to 3.8 (P=0.025) and EQ-5D improved from -0.30 to 0.5 (P<0.001) between baseline and 40 days.
Limits of this study
An open-label study with no placebo control and a short follow-up period, limitations the authors identify themselves. A published comment questioned aspects of this study (PMID 25538851). Funding and conflicts not stated in the abstract.
Source
PubMed 24967102 · doi:10.1155/2014/854560
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.